Shahin MS

No ORCID on file · 1 paper in corpus
2018
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
Gynecologic Oncology ·doi:10.1016/j.ygyno.2018.05.029

ObjectivesTo determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients.MethodsAll patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear cell h…